Should I Buy LAB? LAB 2026 Analysis

Should You Buy Standard BioTools Inc (LAB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.410

1 Day change

-1.40%

52 Week Range

1.720

Analysis Updated At

2026/01/26

Standard BioTools Inc (LAB) is not a good buy for a beginner investor with a long-term strategy at this time. The stock is experiencing a declining price trend, weak financial performance, and lacks positive catalysts. Analysts have downgraded the price target, and there are no strong trading signals or influential trading activity to support a buy decision.

Technical Analysis

The technical indicators show mixed signals. The MACD is positive but contracting, RSI is neutral at 51.094, and the stock is trading near its support level of 1.487. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the overall price trend is downward, with a regular market change of -3.73%.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

NULL identified. No recent news or significant trading activity from insiders, hedge funds, or Congress.

Neutral/Negative Catalysts

The stock has a projected negative trend in the next week (-2.43%).

Financial Performance

In Q3 2025, revenue dropped significantly (-56.52% YoY) to $19.55M. Net income improved but remains negative at -$34.69M (+28.77% YoY). EPS also improved to -0.09 (+28.57% YoY), but gross margin declined to 48.51% (-6.22% YoY). Overall, financial performance is weak.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

TD Cowen downgraded the price target from $1.55 to $1.35 and maintained a Hold rating, citing no surprises in the company's financial report and the impact of the announced sale of SomaLogic.

2 Analyst Rating

Wall Street analysts forecast LAB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LAB is 1.35 USD with a low forecast of 1.35 USD and a high forecast of 1.35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

2 Hold

0 Sell

Hold

Current: 1.430

Low

1.35

Averages

1.35

High

1.35

Current: 1.430

Low

1.35

Averages

1.35

High

1.35

TD Cowen

Hold

downgrade

AI Analysis

2025-11-05

Reason

TD Cowen

Price Target

AI Analysis

2025-11-05

downgrade

Hold

Reason

TD Cowen lowered the firm's price target on Standard BioTools to $1.35 from $1.55 and keeps a Hold rating on the shares. The firm said there were no surprises in the print with the company now reporting continuing operations revenue post the announced sale of SomaLogic.

TD Cowen

Buy

Hold

downgrade

2025-08-13

Reason

TD Cowen

Price Target

2025-08-13

downgrade

Buy

Hold

Reason

TD Cowen downgraded Standard BioTools to Hold from Buy with a price target of $1.55, down from $1.60, post the Q2 report. The company sees a lower growth outlook for the core business and less visibility following the sale of SomaLogic. The company's core business trends will continue to be challenged amid macro headwinds, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LAB

Unlock Now

LAB Should I Buy

LAB Should I Buy

Should You Buy Standard BioTools Inc (LAB) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch